Therapeutic Approaches and Targets for Viral Infections


A cutting-edge technique for effectively enhancing humoral and cellular immune responses to protein antigens is DNA immunisation. Either inactivated viruses or constricted viruses are present in viral vaccines. In order to elicit a response, inactive viral vaccines must contain more antigen than live immunisations. They contain viruses that can no longer replicate. A clinically proven effective treatment option, allergy immunotherapy may significantly lessen the patient's allergic symptoms and the need for conventional, symptom-relieving medication. A particular class of medication used to treat viral infections is known as an antiviral drug.




  • Antiviral Medicines


  • Oseltamivir phosphate, also known as Tamiflu® or its generic equivalent,


  • (Trade name: Relenza®) zanamivir


  • peramivir, also known as Rapivab®.


  • Xofluza® (trade name for baloxavir marboxil).


    Related Conference of Therapeutic Approaches and Targets for Viral Infections

    April 14-15, 2025

    15th European Epidemiology and Public Health Congress

    Budapest, Hungary
    June 02-03, 2025

    14th World Congress on Rare Diseases and Orphan Drugs

    Amsterdam, Netherlands
    June 02-03, 2025

    17th Euro-Global Conference on Infectious Diseases

    Amsterdam, Netherlands
    August 28-29, 2025

    8th Pathology and Infectious Disease Conference

    London, UK
    September 22-23, 2025

    11th International Conference on Infectious and Rare Diseases

    Vancouver, Canada
    December 11-12, 2025

    8th Annual Congress on Bacterial, Viral and Infectious Diseases

    Prague, Czech Republic

    Therapeutic Approaches and Targets for Viral Infections Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in